Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Respirent's Fluticasone/Salmeterol vs Advair Diskus in Healthy Volunteers
NCT05085587Phase 1Unknown
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate and salmeterol in asthma (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Maximum Observed Plasma Concentration for Fluticasone Propionate at 36 hours, Maximum Observed Plasma Concentration for Salmeterol at 36 hours and 2 more. Status: unknown.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05085587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085587.